Tarsus Pharmaceuticals, Inc. (TARS)

25.17 -0.09 (-0.36%) 收市：04:00PM EDT

Tarsus Pharmaceuticals, Inc.

15440 Laguna Canyon Road
Suite 160
Irvine, CA 92618
United States
949 409 1801
https://www.tarsusrx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 244

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Bobak R. Azamian M.D.	Co-Founder, President, CEO & Chairman	1.08M	無	無
Mr. Jeffrey S. Farrow	CFO & Chief Strategy Officer	722.95k	無	1962
Dr. Seshadri Neervannan Ph.D.	Chief Operating Officer	759.2k	無	1968
Dr. Elizabeth Yeu Lin M.D.	Chief Medical Advisor & Director	59.12k	無	1978
Mr. David Nakasone	Head of Investor Relations	無	無	無
Dr. Bryan Wahl J.D., M.D.	General Counsel & Corporate Secretary	619.09k	無	1978
Ms. Adrienne Kemp	Senior Director of Corporate Communications	無	無	無
Mr. Matthew Rossen M.B.A.	Vice President of Marketing	無	無	1978
Mr. Scott Youmans	Vice President of Sales	無	無	無
Ms. Dianne C. Whitfield M.S.W.	Chief Human Resources Officer	578.9k	無	1977

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

公司管治

截至 2024年6月1日 止，Tarsus Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：3；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。